APA Citation

Koleini, N., Nickel, B. E., Wang, J., Roveimiab, Z., Fandrich, R. R., Kirshenbaum, L. A., . . . Kardami, E. (2017). Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway. Oncotarget.

Chicago Style Citation

Koleini, Navid, Barbara E. Nickel, Jie Wang, Zeinab Roveimiab, Robert R. Fandrich, Lorrie A. Kirshenbaum, Peter A. Cattini, and Elissavet Kardami. "Fibroblast Growth Factor-2-mediated Protection of Cardiomyocytes From the Toxic Effects of Doxorubicin Requires the MTOR/Nrf-2/HO-1 Pathway." Oncotarget 2017.

MLA Citation

Koleini, Navid, et al. "Fibroblast Growth Factor-2-mediated Protection of Cardiomyocytes From the Toxic Effects of Doxorubicin Requires the MTOR/Nrf-2/HO-1 Pathway." Oncotarget 2017.

Warning: These citations may not always be 100% accurate.